Carcinoma, Ovarian Epithelial: all 1,619 studies
Page 1 of 17. Open to participants first (245), then studies with results posted, then the rest; newest registration first within each.
- Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian CancerNot yet recruitingNCT07859215Phase 3
- Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian CancerRecruitingNCT07851025Phase 3
- Homologous Recombination Repair Deficiency (HRD) Testing in Newly Diagnosed Advanced-stage Epithelial Ovarian Cancer in ItalyNot yet recruitingNCT07825181
- Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian CancerRecruitingNCT07816666Phase 3
- Efficacy and Safety of BG-C9074 With Bevacizumab Compared With Bevacizumab in Adults With Ovarian, Fallopian Tube, or Primary Peritoneal CancersNot yet recruitingNCT07811271Phase 3
- 89Zr-DFO-Mirvetuximab PET/CT Imaging for Companion Diagnosis and Response Evaluation in Ovarian CancerNot yet recruitingNCT07790939Early Phase 1
- Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian CancerNot yet recruitingNCT07776171Phase 2
- Whole Body Metabolic Activity as a Reflection of Tumor Metabolic Dysregulation and a Predictor of Treatment Response in Ovarian CancerRecruitingNCT07764133
- [68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology IndicationsRecruitingNCT07702292Phase 2
- IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian CancerNot yet recruitingNCT07674615Phase 1
- Blood-Based Minimal Residual Disease in Advanced Epithelial Ovarian Cancer After 1st Line TherapyNot yet recruitingNCT07670962
- Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2RecruitingNCT07617753Phase 1/2
- Sentinel Lymph Node Mapping in Early-Stage Epithelial Ovarian Cancer SurgeryNot yet recruitingNCT07593339Not applicable
- Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian CancerNot yet recruitingNCT07591831Phase 2
- Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian CancerRecruitingNCT07589543Phase 1/2
- A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal CancerNot yet recruitingNCT07545460Phase 3
- Single-arm, Prospective Clinical Trial of Efficacy and Safety of Daphnetin Capsules Combined With TC Regimen for Targeted Maintenance Therapy After Initial Treatment of Stage III-IV Epithelial Ovarian Cancer (RO/R1)RecruitingNCT07495397Not applicable
- Benmelstobart in Combination With Anlotinib and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial OvariaN, Fallopian Tube, or Primary Peritoneal CancerNot yet recruitingNCT07489300Phase 2
- Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)RecruitingNCT07480954Phase 1/2
- Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian CancerNot yet recruitingNCT07454018Phase 2
- [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology IndicationsRecruitingNCT07432633Phase 1/2
- Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid TumorsRecruitingNCT07334119Phase 1
- A Study of Isoquercetin in People With Ovarian CancerRecruitingNCT07303894Phase 2
- Losartan and Paclitaxel in Platinum Resistant Ovarian CancerNot yet recruitingNCT07265739Phase 2
- AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian CancerRecruitingNCT07218809Phase 3
- Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian CancerRecruitingNCT07171528Phase 2
- Centralization and Oncologic Outcomes in Ovarian CancerRecruitingNCT07075939
- Minimally Invasive Interval Debulking Surgery in Advanced Ovarian CancerNot yet recruitingNCT07031908
- Ultrasound Training Program for Gynecologic Cancer Staging in ResidentsNot yet recruitingNCT07028229Not applicable
- A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)RecruitingNCT06994195Phase 3
- SHR - A1811 Injection in the Treatment of Platinum-sensitive Recurrent Ovarian CancerNot yet recruitingNCT06990516Phase 1/2
- SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian CancerNot yet recruitingNCT06990503Phase 3
- Total Neoadjuvant 6 Cycles of Chemotherapy Versus 3 Cycles in Partial Responder Patients Diagnosed With Epithelial Ovarian CancerNot yet recruitingNCT06980545Phase 3
- Phase II Study of Utidelone Plus Fruquintinib Combination Therapy for Platinum-Resistant Recurrent Ovarian CancerNot yet recruitingNCT06973421Phase 2
- Exosome-based Recurrence Score for Post-Treatment Ovarian CancerNot yet recruitingNCT06925126
- Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal CancerRecruitingNCT06915025Phase 3
- Study of the Impact on Survival of a Paradigm Shift in the Therapeutic Strategy of Patients With Advanced Ovarian CancerRecruitingNCT06907771
- Combined Intraperitoneal Chemotherapy Regimen After Optimal Interval Surgery in Advanced Ovarian Cancer: BICOV-1 (Bidirectional Chemotherapy in Ovarian Cancer)RecruitingNCT06902467Not applicable
- A Clinical Study on Fasudil Hydrochloride for Treatment of Gene-Specific Ovarian CancerRecruitingNCT06890858Phase 2
- A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.RecruitingNCT06890338Phase 2
- A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ovarian CancerNot yet recruitingNCT06887933Phase 4
- Lipid Mediators & Cancer: Montelukast, SPM, and AlmondsNot yet recruitingNCT06887673Early Phase 1
- Laparoscopic Interval Cytoreductive Surgery in Advance Ovarian CancerRecruitingNCT06883409Not applicable
- Retrospective Evaluation of Minimally-Invasive Surgical Strategies in Ovarian Neoplasms (REMISSION Study)RecruitingNCT06879730
- Paclitaxel Lipid Suspension for Patients with Platinum-Resistant /Refractory Ovarian CancerNot yet recruitingNCT06867562Phase 3
- SCT-001 CAR T Cells Therapy for Relapsed and Refractory Ovarian CancerNot yet recruitingNCT06846424Phase 1
- ChemoINTEL Assay Algorithm Development Study: In-Vitro Cytotoxic Drug Induced Apoptosis Correlation with Patient Clinical Response to Administered Chemotherapy in PatientsRecruitingNCT06844136
- PARPi and Ovarian Cancer SurvivalNot yet recruitingNCT06838429
- Measure of Outcomes in Patients With Advanced Ovarian Cancer According to Homologous Recombination Status and Matched Therapies in a Real-world ScenarioRecruitingNCT06836219
- Niraparib Versus Bevacizumab As Maintenance Therapy in Patients with De Novo Ovarian Cancer Without Homologous Recombination DeficiencyRecruitingNCT06827353
- Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)RecruitingNCT06819007Phase 3
- Ovarian Cancer Radiomics Approach in CT Led EvaluationRecruitingNCT06817174
- Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian CancerRecruitingNCT06791460Phase 2/3
- Genetic Landscape in Women with Metastatic Ovarian Cancer Before and During Treatment with PARP InhibitorsRecruitingNCT06785077Not applicable
- Impact of Different BRCA1/2 Gene Variants on Response to Therapy and Prognosis of Ovarian CancerRecruitingNCT06775470
- CT-95 in Advanced Cancers Associated With Mesothelin ExpressionRecruitingNCT06756035Phase 1
- JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian CancerNot yet recruitingNCT06751485Phase 3
- EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial SarcomaNot yet recruitingNCT06748872Phase 1
- Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian CancerRecruitingNCT06735326Phase 2
- A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid TumorsNot yet recruitingNCT06724263Phase 2
- CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.RecruitingNCT06690775Phase 2
- Ultrasound-guided Tru-cut Biopsy in Patients with Suspected Ovarian Cancer: Adequacy, Accuracy, Safety and Patient Assessment.RecruitingNCT06689605
- Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian CancerRecruitingNCT06686030Phase 2
- The Application of Sentinel Lymph Node Mapping Technique in the Surgery of Early Epithelial Ovarian CancerNot yet recruitingNCT06673511Not applicable
- Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer.RecruitingNCT06660511Early Phase 1
- NEoadjuvant Olaparib Combination OvArian Cancer Targeted StudyNot yet recruitingNCT06650709Phase 2
- Ultrasensitive SERS Platform With Highly Efficient Enrichment of Analyte for Screening and Diagnosis of Epithelial Ovarian CancerRecruitingNCT06640348
- Exploratory Study on the Correlation Between HRD Score and PARPi Efficacy Based on Chinese Ovarian Cancer PatientsRecruitingNCT06622798
- The Role of CircDENND4C in Epithelial Ovarian CancerNot yet recruitingNCT06617585
- Niraparib Maintenance Treatment in Patients With Newly Diagnosed Advanced Platinum- Sensitive, OC. The First Poland RWE Study.RecruitingNCT06614790
- Surgery for Relapsed Ovarian Cancer in PrecisionNot yet recruitingNCT06602063Phase 1/2
- Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian CancerNot yet recruitingNCT06600841Phase 2
- A Study of Niraparib in Combination With Abemaciclib for Late Line Treatment of Ovarian Cancer (NICHOL TRIAL)RecruitingNCT06594679Phase 1/2
- Neoadjuvant RC48 Plus Carboplatin for HER2-expressing Advanced Ovarian CancerNot yet recruitingNCT06574763Phase 2
- An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian CancerRecruitingNCT06560112Phase 2
- Exosome-based OCS Scores for Predicting Ovarian Cancer RecurrenceNot yet recruitingNCT06558019
- High Definition Profiling of Ovarian Cancer AscitesNot yet recruitingNCT06553742
- Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian CancerNot yet recruitingNCT06552858Phase 2
- Secondary Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for PARP Inhibitors Resistance PatientsNot yet recruitingNCT06544460Phase 2
- Efficacy and Safety of AK104 (PD-1/CTLA-4 Bispecial Antibody) Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian CancerNot yet recruitingNCT06542549Phase 3
- Fluzoparib Neoadjuvant Therapy for Ovarian CancerRecruitingNCT06541314Phase 2
- A New Fast DWI-based MR Protocol for Surveillance in Patients With a High Risk of Ovarian Cancer Recurrence During PARP-inhibitors Maintenance to Enhance Secondary Cytoreduction ResultsNot yet recruitingNCT06541171
- Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian CancerNot yet recruitingNCT06539091Phase 3
- Intraperitoneal Chemotherapy in Recurrent Ovarian CancerNot yet recruitingNCT06535334
- Satisfactory Debulking Prediction Model for Advanced Ovarian Cancer Based on PET-CT Image DataRecruitingNCT06533709
- A Study of QL1706 (an Anti-PD-1/CTLA-4 Combined Antibody) Combined With Albumin-bound Paclitaxel and Bevacizumab in the Treatment of Platinum-resistant Recurrent Ovarian CancerNot yet recruitingNCT06509971Phase 2
- A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian CancersRecruitingNCT06469281Phase 1
- Adebrelimab Plus Chemotherapy, Bevacizumab and Fluzoparib in Platinum-Sensitive Relapsed Ovarian CancerNot yet recruitingNCT06446206Phase 2
- Early Detection of Relapse in Ovarian Cancer Using Capillary Home-sampling and a Protein Biomarker TestRecruitingNCT06445621
- Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian CancerRecruitingNCT06437353Phase 2
- Timing of Surgery After Neoadjuvant Chemotherapy for Advanced Ovarian CancerRecruitingNCT06404671Not applicable
- Safety and Efficacy of Intraperitoneal Injection of METR-NK Cells as Neoadjuvant Therapy for Advanced Epithelial Ovarian CancerRecruitingNCT06395844Phase 1/2
- A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid MalignanciesRecruitingNCT06395519Phase 1/2
- SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian CancerRecruitingNCT06394492Phase 3
- Fasting During Neoadjuvant Chemotherapy in Patient With Epithelial Ovarian CancerRecruitingNCT06386887Not applicable
- Cukurova Score Validation StudyRecruitingNCT06378905
- Application of MRD Combined With Personalized Vaccine in the Treatment of Postoperative Recurrence Prevention of EOCRecruitingNCT06341907Phase 2/3
- SerUm and Plasma MicroRNAs in Malignant Ovarian gERm Cell TumoursNot yet recruitingNCT06329323
- Spatial Radiogenomics of Ovarian CancerRecruitingNCT06324175
- Artificial Intelligence Model for Growth Prediction of Ovarian Cancer OrganoidsRecruitingNCT06317610